The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV), a viral oncogene, is essential for transformation of resting B cells by the virus. We previously demonstrated that LMP1 could repress DNA repair in p53-wild-type and p53-deficient human epithelial cells. In this study, using a host cell reactivation (HCR) assay, we demonstrated that p53-enhanced DNA repair was repressed by LMP1 in p53-deficient cells. Moreover, we found that LMP1 was able to repress p53-dependent transcriptional activity. Regarding the mechanisms of p53 repression by LMP1, we found that LMP1 did not inhibit p53 function through direct interaction, by promoting protein degradation or reducing its DNA-binding ability. Using chimeric proteins in the reporter assay, we demonstrated that LMP1 inhibited p53 transactivation by influencing the N-terminal transactivation domain of p53. Subsequent experiments using various LMP1 deletion mutants indicated that a C-terminus-activating region of LMP1, CTAR1 or CTAR2, is responsible for the repression of p53-mediated DNA repair and p53-dependent transcription, which is correlated with the region responsible for NF-jB activation. Furthermore, blockage of NF-jB signalling by IjB-DN was shown to abolish the repression of p53 by LMP1, suggesting that LMP1 likely repressed p53 function through the NF-jB pathway. Based on these results, we propose that inhibition of p53-dependent transcriptional activity and DNA repair by LMP1 results in the loss of p53 activity for maintaining genomic stability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.
Introduction
Epstein-Barr virus (EBV), a human oncogenic virus, is associated with the development of malignancies such as Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC) (Rickinson and Kieff, 2001) . EBV latent membrane protein 1 (LMP1) is essential for EBVmediated B-cell transformation and induces growth transformation in rodent fibroblast cell lines (Wang et al., 1985; Kaye et al., 1993) . The oncogenic properties of LMP1 can be attributed to several of its functions: increase of cell proliferation and invasion, and inhibition of apoptosis, senescence and differentiation (Wang et al., 1985; Dawson et al., 1990; Henderson et al., 1991; Okan et al., 1995; Yoshizaki et al., 1998; Yang et al., 2000 ; see also the reviews by Eliopoulos and Young, 2001; Li and Chang, 2003) . Recently, we demonstrated that LMP1 could repress DNA repair in both p53-wildtype and p53-deficient human epithelial cells and could enhance DNA-damage-induced micronuclei, which might result in genomic instability and contribute to the oncogenic effects of LMP1 (Liu et al., 2004) .
The p53 tumor suppressor gene regulates various cellular events, such as the cell cycle, apoptosis and DNA repair in response to DNA damage (Levine, 1997) , and plays an important role in maintenance of genomic stability Janus et al., 1999) . Genomic instability has been thought to be highly associated with tumor formation and DNA repair is a major factor in maintaining genomic stability (Hoeijmakers, 2001; Nowak et al., 2002) . Therefore, p53-mediated DNA repair may play an essential role in the maintenance of genomic stability by p53. p53 has been shown to be involved in various types of DNA repair, including nucleotide excision repair (NER), base excision repair (BER) and repair of DNA double-strand breaks (DSBs) (Smith and Seo, 2002; Adimoolam and Ford, 2003; Bertrand et al., 2004; Zurer et al., 2004) . Three mechanisms have been proposed by which p53 may regulate NER. Firstly, p53 binds to and modulates the activities of the NER-associated helicases XPB and XPD . Secondly, p53 transcriptionally regulates the expression of the DDB2 and XPC (Hwang et al., 1999; Adimoolam and Ford, 2002) . Thirdly, p53 serves as a chromatin accessibility factor for NER of DNA damage (Rubbi and Milner, 2003) . Therefore, p53-dependent transcriptional activity is important for regulation of NER by p53 (Adimoolam and Ford, 2003) .
Among the human tumor viruses, HPV E6, HTLV1 Tax and HBV HBx disrupt p53-dependent transcriptional activity through distinct mechanisms and repress DNA repair and induce genomic instability, which contribute to viral oncogenesis (Scheffner et al., 1990; Majone et al., 1993; Lee et al., 1995; Smith et al., 1995; Truant et al., 1995; Akagi et al., 1997; Kao and Marriott, 1999; Philpott and Buehring, 1999) . Thus, it seems common for viruses to contribute to carcinogenesis by repressing the activities of p53. In this study, we found that, using a host cell reactivation assay (HCR), EBV LMP1 can repress p53-mediated DNA repair and, using a p53 transactivation report assay, that it can inhibit p53-dependent transcriptional activity. Blockage of NF-kB signalling by IkB-DN abolishes repression of p53 by LMP1, indicating that LMP1 represses p53 function, likely through the NF-kB pathway. Using chimeric proteins, we found that LMP1 inhibits p53 transactivation by influencing the N-terminal transactivation domain of p53. Based on these results, we propose that LMP1 disrupts the activities of p53 in transactivation and DNA repair, which may contribute to the oncogenesis of LMP1 in human epithelial cells.
Results

LMP1 represses p53-mediated DNA repair
Previously, we demonstrated that LMP1 could repress DNA repair in both p53-wild-type and p53-deficient human epithelial cells (Liu et al., 2004) . In this study, we wished to test whether LMP1 influences p53-mediated DNA repair. We used an HCR assay to measure DNA repair activity and found that the expression of p53 enhanced DNA repair in both H1299 and H1299/bcl2 cells (Figure 1a and b) . Then, plasmids expressing either empty vector or LMP1, and either a UV-damaged or untreated firefly luciferase reporter plasmid (pCMVLuc) in the presence or absence of p53 were cotransfected into H1299 and H1299/bcl2. Compared with cells transfected with the empty vector, cells transfected with LMP1 could inhibit the DNA repair mediated by p53 in a dose-dependent manner (Figure 1a and b).
EBV LMP1 inhibits p53 transactivation
Since the transcriptional activity of p53 is important for p53-mediated NER (Adimoolam and Ford, 2003) , we investigated whether EBV LMP1 represses p53-mediated DNA repair by influencing p53-dependent transcriptional activity. Reporters containing three consensus p53-binding sites or the p21 WAF1 promoter fused to luciferase gene (p3PREc-Luc and p21-Luc) were cotransfected into p53-null cells (H1299/bcl2 and Saos2) with the empty vector or plasmid expressing LMP1. In the presence of LMP1, p53 transactivation activity was reduced in H1299/bcl2 cells using the p3PREc-Luc reporter (Figure 2a) . Similar results were obtained with the p21-Luc reporter containing the p21 WAF1 promoter (Figure 2a ). However, both p53 and LMP1 have little effect on the p21/dI-MscI reporter (without the p53-binding sites, Figure 2a ). In another cell line, Saos2, LMP1 also was found to repress the transactivation function of p53 using the p3PREc-Luc and p21-Luc reporters (Figure 2b ). These results indicate that LMP1 blocks p53-dependent transcriptional activity. Increased amounts of LMP1 resulted in a dose-dependent inhibition of p53 transactivation (Figure 2c ). The expression levels of LMP1, p53, p21
WAF1
, and EGFP as a control, also were analysed by Western blotting. LMP1 expression did not interfere with the amounts of p53 and EGFP (Figure 2d ), but the levels of p21 WAF1 were decreased. These data indicate that LMP1 repressed p53 transactivation in the reporter assays and downregulated p53-induced p21 WAF1 expression. Since LMP1 did not interfere with the amounts of p53, the results indicate that LMP1 repression of p53 transactivation did not occur by promoting degradation of p53. We also tested whether LMP1 repressed endogenous and ARF-activated p53. In the U2OS cells, LMP1 repressed both endogenous and ARF-induced p53 transactivation in the reporter assay (Figure 2e ).
LMP1 did not alter the localization or DNA-binding ability of p53
To investigate whether LMP1 repressed p53-dependent transcription by affecting the location of p53, we monitored the location of p53 in the presence or absence of LMP1. In order to monitor the location of p53, it was fused to red fluorescent protein (pDsRed-p53) and LMP1 was fused to green fluorescent protein (pEGFP-LMP1). pDsRed-p53 and pEGFP-C1 or pEGFP-LMP1 were cotransfected to H1299/bcl2 cells. Regardless of the presence of EGFP-LMP1, p53 was localized in the nuclei ( Figure 3a) . As LMP1 did not affect the p53 location, it was asked whether LMP1 repressed p53-dependent transcription by affecting the DNA-binding ability of p53. To answer this question, we carried out H1299 (a) and H1299/bcl2 (b) cells per well in 24-well plates were cotransfected with 100 ng of pRc/CMV empty vector or pRc/ CMV-p53, a plasmid expressing p53, and various amounts of puroLMP1-386 (0-0.25 mg) supplemented with pIRESpuro2 to 0.25 mg, together with 100 ng of a UV-damaged (2000 J/m 2 ) or undamaged pCMV-Luc reporter construct and 5 ng of pRL-CMV as an internal control. At 24 h after transfection, transfectants were collected and assayed for firefly and Renilla luciferase activities as described in Materials and methods (dual luciferase reporter assay). The fold of HCR represents DNA repair activity, calculated as described in Materials and methods. All data presented represent the means and standard deviations of at least three independent experiments Inhibition of p53 by EBV LMP1 M-T Liu et al WAF1 promoter with the p53-binding sites deleted and 5 ng of pRL-CMV as an internal control in each well. Transfectants were collected after 24 h of transfection and assayed for firefly and Renilla luciferase activities as described in Materials and methods (dual luciferase reporter assay). The firefly luciferase activities normalized with Renilla luciferase activities are presented as light units. (b) Repression of p53-dependent transcription by LMP1 in Saos2 cells. Saos2 cells were used to carry out parallel experiments to those described in (a). (c) p53-dependent transcription was repressed by LMP1 in a dose-dependent manner. H129/bcl2 cells were cotransfected with various amounts of puroLMP1-386 (0-250 ng) supplemented with pIRESpuro2 to 250 ng, 250 ng of empty plasmid pRc/CMV (À) or pRc/CMV-p53 ( þ ), 250 ng of reporter plasmid p3PREc-Luc and 5 ng of pRL-CMV as an internal control in each well. The relative luciferase activity from the transfectants in the presence of p53 and absence of LMP1 was set to 1. All data presented represent the means and standard deviations of at least three independent experiments. (d) 4 Â 10 5 H1299/bcl2 cells per well in six-well plates were cotransfected with 1 mg of pRc/CMV-p53, p53 expressing plasmid, or pRc/CMV empty plasmid, various amounts of puroLMP1-386 (0-1 mg) supplemented with pIRESpuro2 to 1 mg and 2 mg of pEGFP-C1 in each well. After 24 h of transfection, transfectants were collected and equal amounts of protein extracts from each well were analysed using Western blotting with anti-p53, LMP1, p21 WAF1 and EGFP antibodies. (e) LMP1 represses endogenous and ARF-induced p53 transcription activity. U2OS cells were cotransfected with the plasmids indicated: 100 ng of pIRESpuro2 (À) or puroLMP1-386 ( þ ), 0, 50, or 250 ng of pEGFP-ARF, supplemented with vector to 250 ng, 100 ng of reporter plasmids p3PREc-Luc containing three p53-binding sites and 5 ng of pRL-CMV in each well. Transfectants were collected 24 h after transfection and assayed for dual luciferase reporter assay. The relative luciferase activity from the transfectants in the absence of LMP1 and pEGFP-ARF was set to 1. All data presented represent the means and standard deviations of at least three independent experiments an electrophoretic mobility shift assay (EMSA) with cell extracts containing p53 with or without LMP1 and the 32 P-labelled synthetic, double-stranded oligonucleotide with the consensus p53-binding sequence. Nuclear extracts from cells transfected with pRc/CMV-p53 and pIRESpuro2 empty vector or puroLMP1-386 were incubated with 32 P-labelled, consensus p53-binding sequences and analysed using EMSA. As shown in Figure 3b , shifted bands of similar intensity were formed in the absence or presence of LMP1. Therefore, expression of LMP1 did not alter the DNA-binding ability or the localization of p53. These data indicate that LMP1 repression of p53-dependent transcription was unlikely to occur by affecting the location or DNAbinding ability of p53.
EBV LMP1 represses the function of the p53 transactivation domain
To investigate whether LMP1 represses p53 by interfering with the p53 transactivation domain, we fused that domain (1-102 a.a.) or the VP16 transactivation domain (413-490 a.a.) to a GAL4 DNA-binding domain ( Figure 4a ) and determined the activities of transactivation using a reporter with consensus GAL4-binding sites. The activity of the p53 transactivation domain was decreased by LMP1 in a dose-dependent manner ( Figure 4b ). In contrast, the function of the VP16 transactivation domain was not influenced by LMP1 (Figure 4b ). To confirm further that LMP1 influences the function of the p53 transactivation domain, we replaced the p53 transactivation domain by the VP16 transactivation domain from wild-type p53 ( Figure 5a ) and determined their transactivation activities using a reporter with consensus p53-binding sites. When residues 1-101 of p53 were replaced by the VP16 transactivation domain (VP16-p53DB-102), this fusion protein lost the transactivation function ( Figure 5b ). When residues 1-60 of p53 were replaced with the VP16 transactivation domain (VP16-p53DB-61), its transactivation activity was greater than wild-type p53 ( Figure 5b ) and transactivation of VP16-p53DB-61 was not inhibited by LMP1 (Figure 5b ). We also analysed the transactivation of wild-type p53 and these fusion proteins by determining the levels of p21 WAF1 . 5 H1299/bcl2 cells per well in 24-well plates were cotransfected with 100 ng of pFL-CMV empty vector, pGAL4, pGAL4-p53TA or pGAL4-VP16, 50 ng of pFR-luc reporter containing five GAL4-binding sites, and with 5 or 50 ng of puroLMP1-386. After 24 h of transfection, dual luciferase reporter assays were performed. The relative luciferase activities from the transfectants in the presence of pFL-CMV and in the absence of LMP1 were set to 1. All data presented represent the means and standard deviations of at least three independent experiments VP16-p53DB-61 activated more expression of p21 WAF1 than did wild-type p53 and the amounts of p21 WAF1 induced were not repressed by LMP1 ( Figure 5c ). As for the reporter assay in Figure 5b , LMP1 did not repress the function of VP16-p53DB-61. Based on these data, we propose that LMP1 represses p53-dependent transcriptional activity by interfering with the p53 transactivation domain.
Identification of the LMP1 domains required for the repression of p53 function
To determine which regions of LMP1 are required for the repression of p53-mediated DNA repair and transactivation, various LMP1 mutants, puroLMP1-350, ÀD189-222, À350D189-222, À231, À188 and ÀD186, were constructed (Figure 6a ). The expression levels of the various LMP1-derivatives were analysed by Western blotting (Figure 6b ). The LMP1 mutants were then used in the HCR assay. Mutants 350, ÀD189-222 and À231 were able to reduce p53-mediated DNA repair to levels similar to wild-type LMP1; however, mutants 350D189-222, -188, and -D186 had lost the ability to repress p53-mediated DNA repair (Figure 6c ). These results indicate that, in the presence of the transmembrane domain, either residues 189-222 (CTAR1) or 350-386 (CTAR2) of LMP1 are responsible for suppression of p53-mediated DNA repair. These mutants were used . Numbering refers to amino-acid residues of the p53 protein (transactivation domain, 1-97 a.a., solid black boxes; DNA-binding domain, 102-292 a.a., striped rectangles; tetramerization and regulatory domains, 323-393 a.a., open boxes). The construct pVP16-p53DB-102 was generated by substitution of a.a. 1-101 of p53 with the transactivation domain of VP16 (413-490 a.a., dotted box, VP16 TA), and pVP16-p53DB-61 was generated by substitution of a.a. 1-60 of p53 with the VP16 TA. (b) 1 Â 10 5 H1299/bcl2 cells per well in 24-well plates were cotransfected with 100 ng of pRc/CMV empty vector, pCMV-p53, pVP16-p53DB-102 or pVP16-p53DB-61, 100 ng of p3PREc-Luc reporter containing three p53-binding sites, and with 5 or 50 ng of puroLMP1-386. Dual luciferase reporter assays were performed after 24 h of transfection. The relative luciferase activities from the transfectants in the presence of pRc/CMV and in the absence of LMP1 were set to 1. All data presented represent the means and standard deviations of at least three independent experiments. (c) 4 Â 10 5 H1299/bcl2 cells per well in six-well plates were cotransfected with 2 mg of pRc/CMV (vector), pRc/CMV-p53, pVP16-p53DB-102 or pVP16-p53DB-61, and with 0.5 mg of pIRESpuro2 (À) or puroLMP1-386 ( þ ). Transfectants were collected after 24 h of transfection and equal amounts of protein extracts from each well were analysed using Western blotting with antibodies to p53 and p21 WAF1 in the p53 transactivation reporter assay. They were cotransfected with the p3PREc-Luc reporter and pRc/ CMV-p53 into H1299/bcl2 cells. Mutants 350, D189-222 and 231 could repress p53 transactivation but mutants 188, D186 and 350D189-222 had lost this ability (Figure 6d ). Induction of NF-kB by these LMP1 5 H1299/bcl2 cells per well in 24-well plates were cotransfected with 100 ng of pRc/CMV empty vector (À) or pRc/CMV-p53 ( þ ), and 250 ng of various LMP1 constructs as described in (a), together with 100 ng of a UV-damaged (2000 J/M 2 ) or undamaged pCMV-Luc reporter construct and 5 ng of pRL-CMV as an internal control. At 24 h after transfection, transfectants were collected and assayed for firefly and Renilla luciferase activities as described in Materials and methods (dual luciferase reporter assay). The fold of HCR represents DNA repair activity, calculated as described in Materials and methods. All data presented represent the means and standard deviations of at least three independent experiments. (d) Domains of LMP1 required for the repression of p53-dependent transcription. Dual luciferase reporter assays for p53 transactivation using the p3PREc-Luc reporter were performed with various LMP1constructs as described in (a). The relative luciferase activity from the transfectants in the presence of p53 and absence of LMP1 was set to 1. (e) Domains of LMP1 required for NF-kB activation. Dual luciferase reporter assays for NF-kB transactivation using the NF-kB-Luc reporter were performed with 250 ng of various LMP1 mutants. The relative luciferase activity of the transfectants in the absence of LMP1 was set to 1. All data presented represent the means and standard deviations of at least three independent experiments mutants was determined using the PathDect NF-kB cisreporting system. Wild-type LMP1 (386) and mutants 350, D189-222 and 231 can induce NF-kB activation, but mutants 188, D186 and 350D189-222 had lost this ability (Figure 6e) . The results are consistent with a previous study: either the C-terminus-activating region, CTAR1 (a.a. 189-222), or CTAR2 (a.a. 350-386) domain of LMP1 triggered the NF-kB signalling pathway and the transmembrane domain is required for NFkB activation (Huen et al., 1995) . Comparison of the essential regions of LMP1 responsible for NF-kB activation and the repression of p53-mediated DNA repair and p53-dependent transcription showed a consistent overlap. The data imply that LMP1 repressed p53 function, likely by induction of the NF-kB signalling pathway.
NF-kB/RelA inhibits p53 function and IkB mutant interferes with LMP1 inactivation of p53 NF-kB and p53 have been demonstrated to mutually interfere with each other's function (Wadgaonkar et al., 1999; Webster and Perkins, 1999) . In this study, we also demonstrated that RelA repressed p53 transactivation (Figure 7a ). To investigate whether LMP1 repressed p53 transactivation by competition for CBP/p300, the expressing plasmids, CBP and p300, were cotransfected to H1299/bcl2 cells. We found that LMP1-induced repression of p53 was not overcome by CBP or p300 (Figure 7b ). To confirm further an LMP1-induced signal repressing p53 function, we used an N-terminally truncated IkB (IkB-DN) to block NF-kB activation. LMP1-mediated p53 repression of transactivation was restored by IkB-DN in a dose-dependent manner (Figure 7c ). LMP1-mediated p53 repression of DNA repair was also restored by IkB-DN (Figure 7d ). Based on these results, we suggest that NF-kB plays an essential role in the repression of p53-dependent transactivation and DNA repair by LMP1. Since IkB-DN/IkB was reported to interact directly with p53 (Chang, 2002; Zhou et al., 2003) , we investigated whether IkB-DN/IkB induced the translocation of p53 to the cytoplasm in the H1299/bcl2 cells. We found that pDsRed-p53 was located at the nucleus (Figure 3a) and IkB-DN was located at both the cytoplasm and nucleus (Figure 7e ). When the H1299/bcl2 cells were cotransfected with both pDsRed-p53 and IkB-DN, p53 was still located at the nucleus and IkB-DN was located at the nucleus (Figure 7e) . Noticeably, although IkB did not affect p53 nuclear localization, IkB was predominantly detected in the nucleus in the presence of p53. As a result, the possibility of a direct, NF-kB-independent interaction between IkB and p53 should be considered.
Discussion
EBV has been associated closely with the development of NPC. A serological prospective study, carried out in our laboratory using antibodies against EBV DNase and virus capsid antigen (VCA) as markers, revealed a relative risk of developing NPC 32.8 times higher for EBV antibody-positive than antibody-negative individuals, over 16 years of follow-up (Chien et al., 2001 ). This result strongly supports the notion that EBV plays an etiological role in the development of NPC. However, how EBV contributes to NPC formation has not been clearly elucidated. In a recent study, we demonstrated that EBV LMP1 protein may induce micronucleus formation, repress DNA repair and enhance sensitivity to DNA-damaging agents in both p53-wildtype and p53-deficient human epithelial cells (Liu et al., 2004) . Based on these results, we proposed that abrogation of DNA repair by LMP1 may induce genomic instability in human epithelial cells and contribute subsequently to the tumorigenesis of NPC.
The tumor suppressor p53 is an essential cellular gatekeeper for normal growth and division and acts to integrate cellular responses, including cell-cycle arrest, apoptosis and DNA repair, to DNA damage and other stresses (Levine, 1997) . In addition, p53 plays an important role in maintaining genomic stability (Harvey et al., 1993; Albrechtsen et al., 1999; Janus et al., 1999; Burt et al., 2000; Honma et al., 2000; Overholtzer et al., 2003) . Since we demonstrated that LMP1 could repress DNA repair in both p53-wild-type and p53-deficient human epithelial cells (Liu et al., 2004) , it seems that LMP1 may repress DNA repair in a p53-independent manner. However, whether LMP1 also represses DNA repair in a p53-dependent manner awaits elucidation.
In this study, using an HCR assay, we first demonstrated that LMP1 repressed p53-mediated DNA repair in p53-null H1299 and H1299/bcl2 cells (Figure 1a and b). As p53 has been shown to exert its biological effect by transactivating many other genes, we carried out a p53-dependent transcription reporter assay using various reporters with consensus p53-binding sequences or the p21 WAF1 promoter to elucidate the mechanism by which LMP1 represses p53-mediated DNA repair. The results obtained indicate that LMP1 is able to repress the transactivation activity of p53 (Figure 2) . Further experiments using fluorescent microscopy indicated that LMP1 (a membrane protein) and p53 (a nuclear protein) were not colocalized (Figure 3a) . Subsequent experiments using EMSA and Western blotting indicated that LMP1 did not affect the DNA-binding ability or abundance of p53 (Figures 2d and 3b) . These results indicate that it is unlikely that LMP1 represses p53-dependent transcription through direct interaction, promoting protein degradation and reducing DNAbinding ability. To corroborate further that LMP1 repressed p53-dependent transcription by influencing the transactivation domain of p53, that domain was fused to a GAL4 DNA-binding domain to generate GAL4-p53TA and the transactivation function of GAL4-p53TA was found to be repressed by LMP1 (Figure 4b ). In contrast, LMP1 did not repress transactivation of VP16-53DB-61, in which the transactivation domain (1-60 a.a.) of p53 was replaced by the VP16 transactivation domain (Figure 5b ). These data indicate that LMP1 represses p53 transactivation by influencing the N-terminal transactivation domain of p53.
NF-kB and p53 have been demonstrated to mutually interfere with each other's function via various mechanisms: p53 repressed NF-kB RelA via the transcriptional integrator p300 (Ravi et al., 1998) ; p53 and RelA mutually repressed by competition of limited amount of CBP (Wadgaonkar et al., 1999; Webster and Perkins, 1999) ; p53 was found to bind RelA directly (Ikeda et al., 2000) and IKK2-mediated NF-kB activation upregulates mdm2 expression, which represses p53 function (Tergaonkar et al., 2002) . In addition, IkBa, an inhibitory subunit of NF-kB complex, was found to bind p53 and interfered with p53 function (Chang, 2002; Zhou et al., 2003) . Therefore, NF-kB seems antagonistic to p53 functions via different pathways. Conversely, NF-kB plays an essential role in p53-induced cell death (Ryan et al., 2000) and doxycycline-induced p53 2 ) or undamaged pCMV-Luc reporter construct and 5 ng of pRL-CMV as an internal control. Dual luciferase reporter assays were carried out 24 h after transfection. The fold of HCR represents DNA repair activity, calculated as described in Materials and methods. All data presented represent the means and standard deviations of at least three independent experiments. (e) H1299/bcl2 cells were cotransfected with pDsRed2-C1 and IkB-DN or pDsRed-p53 and IkB-DN. After 24 h of transfection, cells were fixed and stained with DAPI. Localization of p53 was monitored through red fluorescent protein, localization of IkB-DN was detected by immunofluorescent assay and nuclear DNA was visualized by DAPI staining activation (Fujioka et al., 2004) . Furthermore, p53 can induce NF-kB activation via phosphorylation of RelA by ribosomal S6 kinase 1 (Bohuslav et al., 2004) . These reports suggest that p53 cooperates with NF-kB in cell death. More studies are needed to elucidate the relationship between p53 and NF-kB. In the case of HTLV-1 Tax, it repressed p53 function by interfering with the activity of p53 N-terminal activation domain and this inhibition was involved in NF-kB pathway and p53 phosphorylation (Pise-Masison et al., 1998; Pise-Masison et al., 2000) . Recently, HTLV-I Tax was found to inhibit p53 transcriptional activity by inducing a novel interaction between p65/RelA and p53 (Jeong et al., 2004) . In EBV, NF-kB is one of major signalling pathways induced by EBV LMP1 and essential for LMP1-induced transformation (Cahir McFarland et al., 1999; He et al., 2000) . Importantly, LMP1 not only triggers canonical NF-kB (p65-p50) pathway but has also been demonstrated in the activation of the noncanonical NF-kB pathway, p100 NF-kB2 (Atkinson et al., 2003; Eliopoulos et al., 2003; Saito et al., 2003) . In this study, comparison of the regions of LMP1 required for repression of p53-mediated DNA repair and transcription, and activation of NF-kB, revealed that they were located at either CTAR1 (a.a. 189-222) or CTAR2 (a.a. 350-386) of LMP1 and the transmembrane domain is required for these functions (Figure  6c-e) . Therefore, the effects of LMP1 on activation of NF-kB, repression of p53-mediated transcription and DNA repair seem to be correlated. Blockage of NF-kB by IkB-DN restores LMP1 repression of p53-dependent transcription and DNA repair (Figure 7c and d) , indicating that LMP1-induced NF-kB activation regulates p53 function. It is noteworthy that CBP or p300 did not restore LMP1 repression of p53-dependent transcription (Figure 7b ), suggesting that LMP1 did not repress p53 function through competition for CBP/ p300. Since LMP1 can trigger both canonical NF-kB (p65-p50) and noncanonical NF-kB (p100 NF-kB2) pathways, these two NF-kB pathways may influence p53 via different mechanisms. p53-dependent transcription has been shown to be essential for p53-mediated NER (Adimoolam and Ford, 2003) . Taken together, these data suggest that LMP1 triggers activation of NF-kB, which inhibits p53-dependent transcription and consequent p53-mediated DNA repair. Previously, we demonstrated that LMP1 repressed DNA repair through a p53-independent pathway and CTAR1 (a.a. 189-222), but not CTAR2 (a.a. 350-386), was responsible for repressing DNA repair (Liu et al., 2004) . Therefore, LMP1 can repress DNA repair through p53-dependent and -independent pathways. Based on these data, we propose that, in addition to the many other mechanisms by which LMP1 contributes to tumorigenesis, LMP1 may induce genomic instability through inhibition of DNA repair and disruption of p53 functions, which may be associated with the development of tumors.
DNA repair is essential for maintaining genomic stability (Hoeijmakers, 2001) and is likely an essential mechanism by which p53 contributes to maintaining genomic stability. Among the human tumor viruses, HPV E6, HTLV1 Tax and HBV HBx disrupt p53 function, and repress DNA repair and induce genomic instability (Majone et al., 1993; Lee et al., 1995; Smith et al., 1995; Kao and Marriott, 1999; Philpott and Buehring, 1999) . In a previous study, we demonstrated that EBV LMP1 repressed DNA repair in a p53-independent manner (Liu et al., 2004) . In this study, we found that LMP1 also repressed p53-mediated DNA repair. In the case of HTLV1 Tax, repression of DNA repair occurs through p53-dependent and -independent pathways: inactivation of p53 function, downregulation of PCNA expression and downregulation of b-polymerase expression (Jeang et al., 1990; Kao and Marriott, 1999; Kao et al., 2000b) . HBV HBx represses DNA repair in p53-deficient cells and inhibits p53-dependent DNA repair (Prost et al., 1998; Groisman et al., 1999) . Interestingly, Tax, HBx and LMP1 all sensitize cells to DNA damage (Capovilla et al., 1997; Kao et al., 2000a; Liu et al., 2004) . Comparison of Tax, HBx and LMP1 shows that Tax and HBx are transactivators but LMP1 is a membrane protein. Nevertheless, they seem to share some biological activities: they activate NF-kB, inactivate p53 function, repress DNA repair, sensitize cells to DNA damage and induce genomic instability. Taking these data together, we suggest that the human tumor viruses, HTLV1, HBV and EBV, utilize distinct viral proteins to achieve the same biological effects, which result in the accumulation of unrepaired DNA, consequent genomic instability, and contribute to the oncogenesis of these viruses.
Materials and methods
Cell culture
H1299 cells, a human large cell lung carcinoma cell line with a deletion of the p53 gene (Mitsudomi et al., 1992) , H1299/bcl2 cells, established previously by transfecting a plasmid expressing bcl-2 into H1299 cells (Liu et al., 2004) , Saos2 cells, a human osteogenic sarcoma cell line with a deletion of the p53 gene (Masuda et al., 1987) and U2OS, a human osteosarcoma cell line with wild-type p53 (Florenes et al., 1994) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum.
DNA constructs
The plasmids expressing LMP1 used in this study, puroLMP1-386, puroLMP1-350 and puroLMP1ÀD189-222, were described previously (Liu et al., 2004) . PuroLMP1-350 was generated by introducing a stop codon at position 350 of the amino-acid sequence and puroLMP1ÀD189-222 was deleted at residues 189-222 of the amino-acid sequence of LMP1. The other mutants, puroLMP1-350D189-222, À231, À188 and ÀD186, were generated by insertion of DNA fragments, LMP1-350D189-222, À231, À188 and ÀD186 into puroFlag, which was generated by insertion of the BamHI-XbaI fragment containing the internal ribosome entry site and puromycin-resistant gene from pIRESpuro2 (Clontech) into the BamHI/SmaI sites of pFLAG-CMV2 (Sigma). Fragment LMP1-350D189-222 was amplified by PCR using a forward primer LMP1L with an artificial EcoRI site (5 0 -CTGAATTC GATGGAACACGACCTTG-3 0 ), a reverse primer with an artificial BamHI site (LMP1-350, 5 0 -CGGGATCCTTAAT CATGACTATGACC-3 0 ) and puroLMP1-D189-222 as the template. Fragment LMP1-231 was isolated from puroLMP1-386 digested by EcoRI and NaeI and inserted into the EcoRI/ EcoRV sites of puroFlag and fragment LMP1-188 was isolated from puroLMP1-386 digested by EcoRI and NcoI and inserted into the EcoRI/EcoRV sites of puroFlag. Fragment LMP1-D186 was amplified by PCR using a forward primer LMP1-187 with an artificial EcoRI site (5 0 -CTGAATTCCCATGGA CAACGACACAGTG-3 0 ), a reverse primer LMP1R with an artificial BamHI site (5 0 -CGGGATCCTTAGTCATAG TAGCTTAG-3 0 ) and puroLMP1-386 as the template. pEGFP-LMP1 was generated by insertion of the EcoRIBamHI fragment of puroLMP1-386 into the EcoRI/BamHI sites of pEGFP-C1 (Clontech). pDsRed-p53 was generated by insertion of a PCR fragment, amplified using a forward primer p53-L with an artificial EcoRI site (5 0 -CTGAATTCCATG-GAGGAGCCGCAGTC-3 0 ), a reverse primer p53-R with an artificial BamHI site (5 0 -CGGGATCCGTCTGAGTCAGGC CCTTCTG-3 0 ) and pRc/CMV-p53 as the template, into the EcoRI/BamHI sites of pDsRed2-C1 and pEGFP-C1 (Clontech). These constructs were verified with DNA sequencing. pGAL4 was generated by insertion of a PCR fragment, amplified using a forward primer GAL4-L with an artificial HindIII site (5 0 -ATCTAAGCTTCCTGAAATGAAGCTA CTG-3 0 ), a reverse primer GAL4-R with an artificial EcoRI site (5 0 -CCGGGAATTCGGCGATACAGTCAACTG-3 0 ) and pSG424 as the template, into HindIII/EcoRI sites of pFLAG-CMV2 (Sigma). pGAL4 encodes a Flag fused protein containing GAL4 DNA-binding domain, 1-147 a.a. pGAL4-p53TA was generated by insertion of a PCR fragment, amplified using a forward primer p53-L with an artificial EcoRI site (5 0 -CTGAATTCCATGGAGGAGCCGCAGTC-3 0 ), a reverse primer p53-102A with an artificial BamHI site (5 0 -CGG GATCCGGTTTTCTGGGAAGGGAC-3 0 ) and pRc/CMVp53 as the template, into the EcoRI/BamHI sites of pGAL4. This construct encodes a GAL4-fused protein containing the p53 transactivation domain, 1-102 a.a. pGAL4-VP16 was generated by insertion of a PCR fragment, amplified using a forward primer VP16-413 with an artificial EcoRI site (5 0 -C TGAATTCGGCCCCCCCGACCGATGTC-3 0 ), a reverse primer VP16-L with an artificial BamHI site (5 0 -CGGGATCC ACCGTACTCGTCAATTCC-3 0 ), into the EcoRI/BamHI sites of pGAL4. This construct encodes a GAL4-fused protein containing the VP16 transactivation domain, 413-490 a.a. pVP16-53DB-102 was generated by insertion of a DNA fragment, amplified by PCR using a forward primer p53-102S with an artificial BamHI site (5 0 -CGGGATCCACC TACCAGGGCAGCTACGG-3 0 ), a reverse primer p53-R with an artificial BamHI site (5 0 -CGGGATCCGTCTGAGT CAGGCCCTTCTG-3 0 ) and pRc/CMV-p53 as the template, into the BamHI site of pVP16, which was generated by insertion of the EcoRI/BamHI fragment of pGAL4-VP16 into the EcoRI/BamHI sites of pFLAG-CMV2. This construct encodes a VP16 (413-490 a.a.)-fused protein containing the p53 DNA-binding domain, 102-393 a.a. pVP16-53DB-61 was generated by insertion of a DNA fragment, amplified by PCR using a forward primer p53-61S with an artificial BamHI site (5 0 -CGGGATCCGATGAAGCTCCCAGAATGCC-3 0 ), a reverse primer p53-R and pRc/CMV-p53 as the template, into the BamHI site of pVP16, This construct encodes a VP16 (413-490 a.a.)-fused protein containing the p53 DNA-binding domain, 61-393 a.a. All constructs were verified by DNA sequencing and the expressed proteins were examined by Western blotting analysis using Flag-tag. The plasmid Rc-CMV-65, encoding RelA protein, was kindly provided by Dr Ching-Jin Chang at Institute of Biological Chemistry, Academia Sinica, Taiwan. pEGFP-ARF was generated by ligating the DNA fragment of ARF open reading frame to pEGFP-C1.
Transfection and dual luciferase reporter assay
Plasmid DNA was transfected into H1299/bcl2 and Saos2 cells using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Cells were seeded 1 day before transfection and were 90-95% confluent at the time of transfection. Plasmid DNA and Lipofectamine 2000 were mixed (1 mg to 1.5 ml) in Opti-MEM medium (Invitrogen) and incubated for 20 min, and then added to the culture well containing cells and medium. After 24 h of transfection, cells were harvested and analysed by dual luciferase reporter assay and Western blotting. The dual luciferase reporter assay was carried out according to the manufacturer's instructions (Promega). Various firefly luciferase reporter plasmids were used in this study: for analysis of p53, p3PREc-Luc containing three p53-binding sites in the region upstream of luciferase gene, p21-Luc containing a luciferase gene driven by a p21 WAF1 promoter, p21/dI-MscI containing a luciferase gene driven by a mutant p21 WAF1 promoter with both p53-response elements deleted (Lin et al., 2000) ; for analysis of NF-kB, pNF-kB-Luc (Stratagene) containing five NF-kB-binding sites in the region upstream of the luciferase gene; for analysis of GAL4 binding, pFR-Luc (Stratagene) containing five GAL4-binding sites in the upstream of luciferase gene. For the dual luciferase reporter assay, the luciferase reporter indicated internal control plasmid pRL-CMV (Promega), containing a Renilla luciferase gene driven by the CMV promoter, and the other effector plasmids were cotransfected to cells, using Lipofectamine 2000. At 24 h post-transfection, cells were lysed in 50 ml lysis solution (0.1 M HEPES, pH7.8, 1% Triton X-100, 1 mM CaCl 2 and 1 mM MgCl 2 ) and assayed for firefly luciferase activity using 20 ml aliquots of the lysates. First, 20 ml of Luciferase Assay Reagent II (Promega) was added to the lysates for firefly luciferase activity measurement using a luminescence counter (Packard), and then 20 ml of Stop & Glo Reagent (Promega) was added to the lysates to quench firefly luciferase activity and activate Renilla luciferase activity for measurement using a luminescence counter (Packard). The firefly luciferase activity of each sample was normalized to the Renilla luciferase activity.
Western blotting analysis
The cellular extracts were separated by SDS-PAGE and transferred to Hybond-C super membrane (Amersham Biosciences Ltd). The blot was incubated with blocking buffer (10 mM Tris-HCl, pH 8.0, 0.9% NaCl, and 4% skim milk) for 1 h and reacted with the antibody indicated for 1 h at room temperature. In this study, various antibodies were used: anti-LMP1 CS1-4 (Dako), anti-p53 DO-1 and Pab-240 (Santa Cruz), anti-p21 WAF1 F5 (Santa Cruz), anti-GFP B2 (Santa Cruz) and anti-Flag M2 (Sigma). After washing three times with washing buffer (10 mM Tris-HCl, pH 7.4, 0.9% NaCl, 0.2% Tween-20), the blot was incubated for 1 h at room temperature with horseradish peroxidase-labelled goat anti-mouse IgG (Amersham Biosciences Ltd.) diluted 1 : 2500 with blocking buffer. After incubation, the blot was washed three times in washing buffer and once in water, and then developed with a freshly prepared substrate (ECL Western blotting, Amersham Biosciences Ltd). The luminescence was detected by a short exposure to X-ray film.
Electrophoretic mobility shift assay (EMSA)
The EMSA was as described previously (Lin et al., 2000) . Equivalent amounts of nuclear extract were used in the EMSA reaction. A synthetic oligonucleotide containing the downstream p53-binding site (À1397 to À1371, AGGAAGAA-GACTGGGCATGTCTGGGCA) of the p21 WAF1 promoter was labelled with 32 P as the probe. Reaction mixtures consisted of 0.02 pmol of labelled probe and 5 mg of nuclear extract protein in a buffer consisting of 20 mM HEPES (pH 7.9), 4 mM Tris-HCl (pH 7.9), 25 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, 1 mM MgCl 2 , 0.3 mg/ml bovine serum albumin and 10% glycerol. Poly[d(I.C)] (2 mg) was added as nonspecific competitor DNA, and the final volume of the reaction mixtures was adjusted to 25 ml. Following incubation at 251C for 20 min, the reactions were loaded onto a 4% polyacrylamide gel (acrylamide : bisacrylamide 29 : 1, w/w) in 0.5 Â TBE (45 mM Tris-borate, 1 mM EDTA, pH 8.0) and electrophoresed at 250 V at 41C. The gels were dried and DNA-protein complexes were detected by exposure to X-ray film.
HCR assay
The HCR assay was as described previously (Liu et al., 2004) . Purified firefly luciferase reporter plasmid DNA (pCMV-Luc), either damaged with 2000 J/m 2 of UV light or mock treated, an undamaged Renilla luciferase pRL-CMV reporter (Promega) as the internal control and effector plasmids (LMP1 and LMP1 mutants) were cotransfected into cells with Lipofectamine 2000 (Invitrogen). At24 h post-transfection, cells were lysed in 50 ml lysis solution (0.1 M HEPES, pH 7.8, 1% Triton X-100, 1 mM CaCl 2 and 1 mM MgCl 2 ) and assayed for firefly luciferase activity using 20 ml aliquots of the lysates. First, 20 ml of Luciferase Assay Reagent II (Promega) was added to the lysates for measurement of firefly luciferase activity using a luminescence counter (Packard), then 20 ml of Stop & Glo Reagent (Promega) was added to the lysates to quench the firefly luciferase activity and activate the Renilla luciferase activity for measurement using a luminescence counter (Packard). The firefly luciferase activity of each sample was normalized to the Renilla luciferase activity. To determine the ability to repair DNA, two parameters, repair conversion and fold of HCR, were calculated as follows: repair conversion was calculated by dividing the normalized firefly luciferase activity from cells transfected with UV-irradiated pCMV-Luc by that of nonirradiated pCMV-Luc tansfectants. The fold of HCR was calculated by dividing the repair conversion of effector transfectants by that of vector transfectants. Data from at least three independent experiments were averaged to calculate the mean and the standard deviation.
